Clinical Trial Update: Efficacy and Safety of Rivastigmine in Patients With Traumatic Brain Injury and Cognitive Impairment [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating rivastigmine for cognitive impairment after traumatic brain injury has completed, reporting efficacy and safety outcomes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Traumatic Brain Injury

Drugs mentioned

• Rivastigmine (Rivastigmine)

Snippet

Sponsor: Novartis | Conditions: Traumatic Brain Injury | Phase 3 | Status: COMPLETED